Compared with developed countries, there is still a large gap in the level of drug R & D in China, with more follow-up R & D and relatively lack of breakthrough innovation
Weisi medical transferred to scientific and technological innovation board, and there are hidden dangers in the proportion of R & D and sales
Time of Update: 2019-12-24
Original author: at that time, it was common for the three board enterprises to move to the science and technology innovation board
Would these three board enterprises
Readjustment of R & D pattern of pharmaceutical enterprises and operation focus of foreign enterprises
Time of Update: 2019-11-29
Under the background that the government encourages new drug research and development, Chinese cro and CMO enterprises will usher in more development opportunities and gain more market share.
Another multinational pharmaceutical company, China's early R & D center closed
Time of Update: 2019-11-19
On September 25, 2018, Novartis announced that it plans to cut more than 2200 jobs in its headquarters in Switzerland, which will affect 1500 front-line pharmaceutical production employees and about 700 employees in the commercial service department.
Dealway (China) Shanghai R & D center officially opened
Time of Update: 2019-11-11
Xiong Shaobo, deputy general manager of Fuda company, also said that in the future, Fuda company will work with dealway to make contributions to the R & D and innovation of thermal insulation materials and coating products.
International | aiside won the "Oscar" award of American science and technology circle - 100 innovation award of R & D
Time of Update: 2019-11-05
On November 1, axalta announced that its innovative voltatex ® 4224 high thermal conductivity impregnating resin won the "Oscar" award in the US scientific and technological
Dialogue with President of Takeda global R & D: is Takeda a M & A or R & D enterprise
Time of Update: 2019-11-03
"Before we mentioned that China joined the world, today we want China to help or even lead the world!" At a media communication meeting held by the center on October 29, Wang Yu
Yunnan Baiyao released the third quarter report, with increased R & D investment and emphasis on strengthening the layout of biological drugs
Time of Update: 2019-10-29
At present, there are 6 drugs under research in the pipeline of antibody pharmaceutical products in China, focusing on the field of immune diseases.